- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Lee Schwartzberg Explains the Promise of Liquid Biopsies in Cancer
As the technology improves, we’re going to see liquid biopsies used in multiple different cancers, explained Lee Schwartzberg, MD, FACP, executive director, West Cancer Center.
As the technology improves, we’re going to see liquid biopsies used in multiple different cancers, explained Lee Schwartzberg, MD, FACP, executive director, West Cancer Center.
Transcript
Liquid biopsies have shown promise in lung cancer and most recently in breast cancer. Do you think use of these biopsies will become more prevalent in the future?
I think liquid biopsies are going to be very important in the precision oncology world of tomorrow. I just returned from AACR [American Association for Cancer Research], and there were many presentations in 2019 about liquid biopsies. So, the technology is developing very quickly. The idea that tumors shed both cells and circulating tumor DNA, as well as other some subcellular molecules like microRNA and proteins into the blood stream, means that really the blood is a rich source of understanding the dynamics of how tumors grow and shrink. So, as the technology improves, and as the studies are done to show concordance against tissue biopsies, we’re going to see liquid biopsies used in multiple different directions.
Right now, they’re good for when you don’t have a tissue biopsy available or there’s a limited sample or not enough to do next-generation sequencing, for example, we can get those results from a liquid biopsy. I think in metastatic cancer, it’s going to be very useful to monitor patients to see what happens, because tumors unfortunately change over time. They can find resistance mechanisms to get around some of the medicines we use. And of course, there’s a lot of interest in early diagnosis using liquid biopsies, and many companies are working on tests that can be used broadly to screen patients for cancer when they have no symptoms. So, we’re very excited about the entire spectrum of liquid biopsies. There’s a lot of work that needs to be done. There’s a lot of clinical trials to show the clinical utility, but the validation—technical validation and the clinical validation—has already been largely done.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Ways Providers, Payers Can Ensure Biomarker Testing Is Done in Cancer Care
October 18th 2024There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.
Read More
